NantHealth Inc (NYSE:NH) COO Ronald Allen Louks sold 26,820 shares of NantHealth stock in a transaction dated Friday, October 6th. The stock was sold at an average price of $4.28, for a total transaction of $114,789.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of NantHealth Inc (NYSE:NH) traded down 4.06% during trading on Tuesday, reaching $4.02. 243,063 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $4.44 and its 200 day moving average price is $4.44. The firm’s market capitalization is $490.22 million. NantHealth Inc has a 52 week low of $3.96 and a 52 week high of $13.80.

NantHealth (NYSE:NH) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The firm had revenue of $26.23 million for the quarter, compared to analysts’ expectations of $31.28 million. During the same period in the prior year, the company posted ($0.15) earnings per share. NantHealth’s quarterly revenue was down 16.7% compared to the same quarter last year. Analysts predict that NantHealth Inc will post ($0.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/10/nanthealth-inc-nh-coo-ronald-allen-louks-sells-26820-shares.html.

A number of equities analysts have issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $5.00 target price on shares of NantHealth in a research report on Thursday, September 28th. BidaskClub upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. Finally, Canaccord Genuity restated a “buy” rating and set a $6.00 target price (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $9.25.

Hedge funds have recently bought and sold shares of the business. TIAA CREF Investment Management LLC lifted its stake in NantHealth by 68.6% during the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after buying an additional 8,217 shares in the last quarter. Alliancebernstein L.P. purchased a new stake in shares of NantHealth in the second quarter worth approximately $102,000. Bank of America Corp DE lifted its position in shares of NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock worth $125,000 after purchasing an additional 19,694 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of NantHealth in the second quarter worth approximately $121,000. Finally, Teachers Advisors LLC lifted its position in shares of NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after purchasing an additional 24,588 shares in the last quarter.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.